with either a BRAF fusion or rearrangement or BRAF V600 mutation based on the results of the FIREFLY-1 study. Ipsen's deal includes $71 million in cash and another $40 million in equity and comes ...

The common effect through all these breakpoint variants is the formation of an oncogenic BRAF–KIAA1549 fusion incorporating the BRAF kinase domain, but lacking the amino-localized autoinhibitory ...

and seven cases of stable disease in those with BRAF fusion-positive solid tumors. Fore said it is hoping to submit an application seeking accelerated approval for plixorafenib in BRAF V600 primary ...

In its normal state, the BRAF protein remains confined to an inactive form, through a mechanism of auto-inhibition that is critical for preserving the fine, correct regulation of the MAPK pathway.

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

Over the past decade, a U.K.-based nuclear propulsion startup has been working behind the scenes to develop a fusion rocket that could cut flight time to Mars in half. This week, it unveiled the ...

This publication provides a worldwide survey of public and private fusion devices with experimental and demonstration designs, which are currently in operation, under construction or being planned. It ...